A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (SEACRAFT-1)
An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations
Sponsor: Erasca, Inc.
A PHASE1 clinical study on Advanced or Metastatic Solid Tumors, this trial is ongoing. The trial is conducted by Erasca, Inc. and has accumulated 18 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
18 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
▶ Show 13 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Erasca, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .